NZ Approves MDMA for Severe PTSD Treatment — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Medsafe approved two psychiatrists to prescribe pharmaceutical-grade MDMA to adults with severe PTSD on Friday, making New Zealand only the second country to allow the drug's therapeutic use after Australia in 2023.
- Deputy Prime Minister David Seymour publicly backed the approval as an "innovative treatment" for a condition that "ruins lives," and noted he previously supported legalizing magic mushrooms for severe depression.
- The US FDA rejected legalizing MDMA's medicinal use in 2024 citing insufficient evidence of safety and effectiveness, though clinical trials continue; current US pharmaceutical PTSD options remain limited to two antidepressants requiring three months of dosing with uneven response rates.
- An Israeli study found MDMA taken by partygoers at the Nova music festival during the 7 October Hamas attacks helped cushion the trauma they endured, cited as real-world evidence supporting therapeutic potential.
- New Zealand's Ministry of Health specified that treatment combines MDMA with psychotherapy in controlled clinical settings under authorized psychiatrists, with no take-home drugs and patients required to be 18 or older.
Why it matters: With the FDA rejecting MDMA in 2024 and existing US PTSD drugs requiring three months of dosing with uneven results, New Zealand's approval gives severe-PTSD patients a faster-acting psychotherapy adjunct — but the narrow rollout (just two prescribers, no take-home drugs, controlled clinical settings, 18+ only) means immediate access remains tightly rationed.
Ask SkimNews
